Sulfametomidine

Sulfametomidine

SCHEMBL30336540

COc1cc(NS(=O)(=O)c2ccc(N)cc2)nc(C)n1

nearest known ligand 0.76

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 6/20 0.76
ALDH1A1 P00352 6/20 0.76
LMNA P02545 4/20 0.76
CYP3A4 P08684 3/20 0.76
PDE4A P27815 1/20 0.71
AGO2 Q9UKV8 1/20 0.71
CYP2C19 P33261 3/20 0.66
SMN1; SMN2 Q16637 3/20 0.63
MAPT P10636 3/20 0.54
CYP2C9 P11712 1/20 0.54
RAB9A P51151 1/20 0.54
ADRA1A P35348 1/20 0.53
KDM4E B2RXH2 2/20 0.53
APEX1 P27695 1/20 0.53
BLM P54132 1/20 0.53
NPSR1 Q6W5P4 1/20 0.53
TDP1 Q9NUW8 1/20 0.52
KMT2A Q03164 1/20 0.52
AKT1 P31749 1/20 0.52
HTT P42858 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Sulfametomidine SCHEMBL151238 1.00 HTR6 (0.76) HTR6ALDH1A1LMNACYP3A4PDE4A
Sulfametomidine SCHEMBL11123046 0.99 ALDH1A1 (0.74) HTR6ALDH1A1LMNACYP3A4PDE4A
Sulfametomidine SCHEMBL13723980 0.89 LMNA (0.70) HTR6ALDH1A1LMNACYP3A4PDE4A
Sulfametomidine SCHEMBL28142816 0.88 KMT2A (0.71) HTR6ALDH1A1LMNACYP3A4PDE4A
SCHEMBL7837632 0.88 HTR6 (0.78) HTR6ALDH1A1LMNACYP3A4PDE4A
Sulfadimethoxine SCHEMBL93845 0.86 LMNA (1.00) HTR6ALDH1A1LMNACYP3A4PDE4A
Sulfadimethoxine SCHEMBL29363944 0.86 LMNA (1.00) HTR6ALDH1A1LMNACYP3A4PDE4A
Sulfadimethoxine SCHEMBL2430279 0.85 LMNA (0.97) HTR6ALDH1A1LMNACYP3A4PDE4A
SCHEMBL7833927 0.84 HTR6 (0.72) HTR6ALDH1A1LMNACYP3A4PDE4A
Sulfisomidine SCHEMBL34791 0.83 PDE4A (1.00) HTR6ALDH1A1LMNACYP3A4PDE4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120022878-A Amphiphilic covalent organic framework mixed mode chromatographic stationary phase and preparation method and application thereof 河南工业大学 2025-05-23 CN claimed
CN-118771578-B Method for degrading new pollutants based on amino-modified iron coordination polymer activated peroxyacetic acid 同济大学 2025-01-21 CN claimed
CN-110891562-B Lithium salts of N-substituted glycine compounds and uses thereof 心悦生医股份有限公司 2024-07-16 CN claimed
CN-113365623-B Antiandrogens for the treatment of metastatic castration-sensitive prostate cancer 阿拉贡药品公司 2025-06-24 CN disclosed
CN-115667235-B Compositions and methods for treating disorders ameliorated by muscarinic receptor activation 卡鲁娜治疗学有限公司 2025-06-17 CN disclosed
CN-120022878-A Amphiphilic covalent organic framework mixed mode chromatographic stationary phase and preparation method and application thereof 河南工业大学 2025-05-23 CN disclosed
CN-116209446-B 7- (Piperidin-1-yl) -4H-pyrimido [1,2-B ] pyridazin-4-one derivatives as positive allosteric modulators of muscarinic acetylcholine receptor M4 范德堡大学 2025-05-13 CN disclosed
CN-110573184-B RNA nanostructures, methods of making and uses thereof 俄亥俄州立创新基金会 2025-05-13 CN disclosed
CN-112424197-B Difluoromethyl-phenyltriazoles as modulators of GABA receptors 勃林格殷格翰国际公司 2025-04-22 CN disclosed
CN-119855901-A Tiling receptor-ligand reprogramming chemotaxis via display peptides 加利福尼亚大学董事会 2025-04-18 CN disclosed
CN-119613404-A Organic compound 细胞内治疗公司 2025-03-14 CN disclosed
CN-110740993-B Deuterated pyridonamides and prodrugs thereof useful as sodium channel modulators 沃泰克斯药物股份有限公司 2023-09-01 CN disclosed
CN-111848577-B N- (hetero) aryl-substituted heterocyclic derivatives useful in the treatment of diseases or conditions associated with the central nervous system 克罗诺斯治疗有限公司 2023-09-01 CN disclosed
CN-116600803-A Macrocyclic urea orexin receptor agonists 默沙东有限责任公司 2023-08-15 CN disclosed
CN-116490180-A Methods of treating CNS disorders 杭州高光制药有限公司 2023-07-25 CN disclosed
CN-111093664-B Organic compound 细胞内治疗公司 2023-06-02 CN disclosed
CN-116209446-A 7- (piperidin-1-yl) -4H-pyrimido [1,2-B ] pyridazin-4-one derivatives as positive allosteric modulators of muscarinic acetylcholine receptor M4 范德堡大学 2023-06-02 CN disclosed
CN-116178391-A Forward allosteric modulators of muscarinic acetylcholine receptor M4 范德比尔特大学 2023-05-30 CN disclosed
CN-116041365-A Muscarinic acetylcholine receptorsBody M 4 Positive allosteric modulators of (2) 范德比尔特大学 2023-05-02 CN disclosed
CN-112118831-B Tabletted chewing gum sweet suitable for active pharmaceutical ingredient 费尔廷制药公司 2023-04-21 CN disclosed